Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Aldeyra Therapeutics, Inc. Clear all
Completed Phase 3 Interventional Results available

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

NCT03131154
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

NCT03012165
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of ADX-102 Ophthalmic Drops
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Morrow, Georgia • Kansas City, Missouri • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT03404115
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Waterbury, Connecticut • Indianapolis, Indiana • Lewiston, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

NCT03916042
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

NCT05487404
View directory record Official record
Conditions
Ethanol Intoxication
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

NCT02406209
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
NS2, Prednisolone acetate ophthalmic suspension (1%)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Lancaster, California • Golden, Colorado • Hamden, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

NCT04908514
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-629 (Open-label)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

NCT03162783
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), ADX-102 Ophthalmic Lipid Solution (0.5%)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT05062330
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raynham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04735393
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192
View directory record Official record
Conditions
Chronic Cough
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

NCT04847544
View directory record Official record
Conditions
Covid19
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06493604
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

NCT06685692
View directory record Official record
Conditions
Alcohol Hepatitis
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Bradenton, Florida • Tampa, Florida • Dallas, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Study in Subjects With Retinitis Pigmentosa

NCT05392179
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
ADX-2191
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 7, 2026, 10:44 AM EDT
Withdrawn Phase 2 Interventional

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

NCT05599815
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06424444
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Shelby, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

NCT03660878
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 7, 2026, 10:44 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

NCT07402876
View directory record Official record
Conditions
Primary Vitreoretinal Lymphoma
Interventions
ICM ADX-2191 injection, Monthly ADX-2191 injection
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 7, 2026, 10:44 AM EDT